Home
Invest
Explore
About
Pricing

Search

Sign In
IMU
Asset Logo

Imugene

πŸ‡¦πŸ‡Ί ASX

🧬 BIOTECHNOLOGY

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸƒ Esg

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

+ 6.67%
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

134
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

πŸ“ˆ Performance

Price History

+302.66%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸƒ Environmental, Social and Governance scores ℹ️

🌳

Environmental Score
36

A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution

πŸ•ŠοΈ

Social Score
62

An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.

βš–οΈ

Governance Score
12

An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.04

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in IMU

134

πŸ“Š Total Capital Earnings

$328K

πŸ”ƒ Average investment frequency

35 weeks

πŸ’΅ Average investment amount

$2,022

⏰ Last time a customer invested in IMU

3 hours
IMU investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

8%

100k - 150k

19%

50k - 100k

42%

Less than 50k

27%
πŸ‘Ά Age of investors

18 - 25

26 - 34

37%

35 - 90

57%
πŸ™‹ Legal gender of investors

Female

51%

Male

49%

Pearlers who invest in IMU also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

3.98%

πŸ“Š Share price

$103.05 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

⛳️ DIVERSIFIED

🧱 MATERIALS

πŸ’Έ FINANCIALS

Find Out More

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

21.20%

πŸ“Š Share price

$63.51 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

4.24%

πŸ“Š Share price

$69.62 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

14.55%

πŸ“Š Share price

$140.61 AUD

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

🌏 GLOBAL

πŸ€– TECHNOLOGY

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6041.2m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

πŸ™Œ Performance (5Yr p.a)

4.51%

πŸ“Š Share price

$138.93 AUD

⛳️ DIVERSIFIED

πŸ’Έ FINANCIALS

πŸ‡¦πŸ‡Ί AUSTRALIA

Want more shares? Try these...

πŸ“Š Share price

$0.02 AUD

Ingenia Communities Group engages in managing and developing a portfolio of retirement and lifestyle communities. The company is headquartered in Sydney, New South Wales and currently employs 1,400 full-time employees. The company went IPO on 2004-07-01. The company owns, operates, and develops a portfolio of lifestyle and holiday communities across key urban and coastal markets. The company operates in five segments: Lifestyle Development; Lifestyle Rental; Ingenia Gardens; Ingenia Holidays; and Fuel, Food & Beverage Services. The Lifestyle Development segment comprises of the development and sale of lifestyle homes. The Lifestyle Rental segment comprises of long-term accommodation within lifestyle and rental communities. The Ingenia Gardens segment consists of rental villages. The Ingenia Holidays segment comprises of tourism and rental accommodation within holiday parks. The Fuel, Food & Beverage Services segment consists of the Company’s investment in service station and food & beverage operations adjoined to Ingenia Holiday communities. Its subsidiaries include Bridge Street Trust, Browns Plains Road Trust, Casuarina Road Trust, Edinburgh Drive Trust, and Garden Villages Management Trust.

πŸ™Œ Performance (5Yr p.a)

0.64%

πŸ“Š Share price

$4.57 AUD

🏠 REAL ESTATE

πŸ•ŠοΈ SOCIALLY AWARE

IMPQ.AX was created on 2021-09-29 by Perennial. The fund's investment portfolio concentrates primarily on total market equity. The objective of the Fund is to deliver long-term capital growth predominately through investments in Australian and New Zealand listed smaller and mid-cap companies that are Better Future Investments.

πŸ™Œ Performance (5Yr p.a)

2.67%

πŸ“Š Share price

$4.92 AUD

πŸ’Έ FINANCIALS

Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The company is headquartered in Burnsville, Minnesota. The company went IPO on 2019-08-30. The firm is engaged in designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. Its products include Vision-mitral regurgitation (MR) Ablation Catheter, Advantage-MR electrophysiology (EP) Recorder/Stimulator and Vision-MR Dispersive Electrode. The Vision-MR Ablation Catheter is designed to work under real-time MRI guidance. Advantage-MR EP Recorder/Stimulator System provides technology that allows physicians to utilize both the EP recording system and a cardiac stimulator while ablating within the iCMR environment. The firm sells its products to hospitals and clinics for use in iCMR labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed.

πŸ™Œ Performance (5Yr p.a)

2.49%

πŸ“Š Share price

$1.13 AUD

🩺 HEALTH CARE

Compare
Add to watchlist